The FDA hopes to fully approve the Pfizer vaccine on Monday, The New York Times reported
Dado Ruvic/Reuters
- The FDA is pushing to approve the Pfizer vaccine on Monday, according to The New York Times.
- The new target is reportedly quicker than the previous expected timeline.
- See more stories on Insider's business page.
The Food and Drug Administration is planning to authorize full approval of the Pfizer-BioNTech two-dose COVID-19 vaccine on Monday, according to The New York Times.
The new target is a speeder timeline than the agency originally anticipated for licensing the shot, the outlet reported. The agency had previously set an unofficial deadline for approval by around Labor Day.
On Friday afternoon, regulators still had a " substantial" amount of paperwork and required negotiations with the company to complete before finishing the approval process, according to The Times.
People familiar with the matter told the outlet that some components of the review could possibly push the approval date beyond Monday.
A representative for the FDA did not immediately return Insider's request for comment.
The approval is expected to offer firmer confidence in the vaccine, allowing for a slew of anticipated vaccination mandates among public and private organizations that had been waiting on full authorization before announcing vaccine requirements.
Health experts, too, are eager for an FDA-approved vaccine, in hopes that it will convince some skeptical Americans who have been holding out for a fully authorized shot to get vaccinated.
The move would come one week after the FDA updated its approvals of both Pfizer and Moderna's vaccine to allow for third doses in some immunocompromised people.
from Business Insider https://ift.tt/3mj4S50
No comments